Cardiovascular Systems (CSII) Misses Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Leerink Partners Raises Price Target as Cardiovascular Systems (CSII) Reports Above Preannouncement
May 5, 2016 8:52 AM EDTLeerink Partners reiterated a Market Perform rating on Cardiovascular Systems (NASDAQ: CSII), and raised the price target to $15.00 (from $13.00), following the company's 3Q earnings report. CSII reported sales of $44.5M, slightly above its preannounced range of $43.5M-$44M. Leerink continues to view CSII's longterm... More
Cardiovascular Systems (CSII) Offers Three-Year Data from Pivotal ORBIT II Study
May 5, 2016 8:08 AM EDTCardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) shared three-year results from its pivotal ORBIT II study in a featured clinical research presentation at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) conference in Orlando, Florida.
The ORBIT II study evaluated the safety and efficacy of the companys Diamondback 360® Coronary Orbital Atherectomy System... More



